Retatrutide
Availability Clinical trials only
What it is
Retatrutide is an investigational triple agonist, activating the GLP-1, GIP, and glucagon receptors at once. Eli Lilly is developing it for obesity. The glucagon arm is the addition that matters: it raises energy expenditure rather than only suppressing appetite, which is why it has produced the largest weight reductions yet reported for a drug of this kind.
Why people take it
The numbers, and impatience. Phase 3 results reported through 2026 are the strongest in the field, and people who have plateaued on semaglutide or tirzepatide want the next step now rather than in 2027. That demand is why vials labeled retatrutide have started circulating on gray-market menus, including a few telehealth ones, well ahead of any approval.
How it's delivered
In the trials, a once-weekly subcutaneous injection titrated upward over months under supervision. Outside the trials there is no legitimate supply and no established dose. What circulates outside the trials is unregulated material of unverified identity, purity, and concentration, which is not the same product that was studied even when the label matches.
Where the evidence stands
Strong for weight, with randomized human evidence also supporting glycemic control, liver-fat reduction and knee-pain improvement; longevity benefit is unproven. Lilly's Phase 3 TRIUMPH program has reported average reductions in the range of roughly 22 to 29 percent depending on the trial, dose, and duration, with TRIUMPH-1 landing near 25 percent in one dose group over 80 weeks. Gastrointestinal side effects drove discontinuations, as they do across the class. Preliminary TRIUMPH-3 cardiovascular event analyses have been reported without a demonstrated cardiovascular benefit, and there is no long-term safety record and nothing at all on aging or lifespan. Retatrutide is not approved by any regulator anywhere in the world, and Lilly has signaled a US submission in 2027.
Estimated cost
- No approved product and no legitimate price
- Free to participants inside a clinical trial
- No insurance pathway exists
Who offers it
No one offers retatrutide legitimately. The only lawful route to it today is enrollment in one of the Phase 3 trials, listed on the public registry. Vials sold online as retatrutide, and the handful of gray telehealth menus that list it, sit outside the approval system entirely and have not been tested for what is in them.
Recorded from the trial registry and sponsor announcements on our last research pass. We list no referral path to this treatment and are not compensated for this entry.
Go deeper
No retatrutide guide yet. Our GLP-1 guide covers the approved drugs in the same family and the evidence behind them, which is the comparison retatrutide will eventually be judged against.
Longevity.io is for educational purposes only and is not medical advice. We cover retatrutide because people are already buying it, not because an unapproved vial from an unregulated vendor is a reasonable option. If the drug interests you, the trial registry is the place to look.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
